Watson Pharmaceuticals Inc. April 15 announced that its subsidiary, Watson Laboratories Inc., has received approval from the Food and Drug Administration for its generic version of AstraZeneca’s Toprol XL (metoprolol succinate extended-release tablets).
Toprol is a beta-blocker used to treat angina, heart failure, and high blood pressure, the company said.
Watson said it intends to begin shipping the product next week.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.